Protective effect of Melatonin on clinical outcomes in patients with acute ischemic stroke
Phase 3
Recruiting
- Conditions
- Acute ischemia stroke.Cerebral ischemiaI67.82
- Registration Number
- IRCT20231220060484N1
- Lead Sponsor
- Islamic Azad University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Age:18 to 85 years old
Occurrence of stroke within the past 24 hours
NIHSS score of at least 4 and at most 27
Not eligible for thrombolytic therapy and thrombectomy
Exclusion Criteria
Pregnancy or breastfeeding
Acute or chronic intracranial hemorrhage or aneurism
Any type of cognitive or behavioral disorder
Concurrent inflammatory disease and/or malignancy
Patients with transient ischemic attacks
Sensitivity to Melatonin
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie melatonin's neuroprotective effects in acute ischemic stroke (I67.82)?
How does melatonin compare to standard-of-care treatments in acute ischemic stroke clinical trials?
Are there specific biomarkers that predict melatonin response in cerebral ischemia patients?
What adverse events are associated with melatonin use in acute stroke and how are they managed?
What combination therapies with melatonin show promise in treating acute ischemic stroke?